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Abstract
The death ligand TRAIL represents a promising therapeutic strategy for metastatic melanoma, however prevalent and
inducible resistance limit its applicability. A new approach is presented here for sensitization to TRAIL. It is based on
inhibition of the membrane potassium channel KCa3.1 (IK1), which serves fundamental cellular functions related to
membrane potential. The selective inhibitor TRAM-34 did not induce apoptosis by itself but synergistically enhanced TRAIL
sensitivity and overrode TRAIL resistance in a large panel of melanoma cell lines. Expression of IK1 was also found in
mitochondria, and its inhibition resulted in mitochondrial membrane hyperpolarization and an early activation of Bax. The
combination of TRAM-34 and TRAIL resulted in massive release of mitochondrial factors, cytochrome c, AIF and SMAC/
DIABLO. Bax knockdown and Bcl-2 overexpression abolished apoptosis. Overexpression of XIAP diminished apoptosis by
two-fold, and SMAC knockdown almost completely abolished apoptosis. These data uncover the existence of a rheostat in
melanoma cells, consisting of inhibitor of apoptosis proteins and SMAC, which regulates TRAIL sensitivity. Thus, a new
strategy is described based on mitochondrial membrane channels, which correspond to Bax activation. As both TRAIL and
IK1 inhibitors had shown only minor side effects in clinical trials, a clinical application of this combination is conceivable.
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Introduction
Metastatic melanoma is characterized by unbroken high
mortality [1]. The pronounced resistance to chemotherapy and
to an anti-tumor immune response is related to defects in
proapoptotic signaling [2]. Overcoming apoptosis resistance thus
appears as a promising therapeutic goal. The death ligand TRAIL
(TNF-related apoptosis-inducing ligand) induces apoptosis via
TRAIL-R1/DR4 and TRAIL-R2/DR5 [3], whereas decoy
receptors TRAIL-R3/DcR1 and TRAIL-R4/DcR2 lack the
death domain and may block the pathway [4,5]. TRAIL reveals
the particular advantage of selectively targeting cancer cells, while
normal cells are largely protected [6].
We have previously shown activity of DR4 and DR5 in
melanoma cells. As the receptors were also expressed in melanoma
tissue, TRAIL-based strategies appear as promising also for
melanoma therapy [7]. Permanent TRAIL resistance, seen in
some melanoma cell lines, as well as inducible resistance, seen in
initially sensitive cell lines, may however limit its applicability
[7,8]. Induced TRAIL resistance had been correlated in melano-
ma cells with downregulation of TRAIL receptors, initiator
caspases and proapoptotic Bcl-2 proteins [8,9].
Two main branches of extrinsic and intrinsic apoptosis
pathways have been described [10]. Extrinsic pathways are
initiated by binding of TNF-a, CD95L/FasL or TRAIL to death
receptors, formation of death-inducing signaling complexes
(DISC) and activation of initiator caspases-8 and -10 [11]. On
the other hand, intrinsic pathways are initiated by cellular and
DNA damage and particularly employ mitochondria. The
mitochondrial level is critically controlled by the family of pro-
and antiapoptotic Bcl-2 proteins [12]. Key events are depolariza-
tion of the mitochondrial membrane potential (Dym) and
mitochondrial outer membrane permeabilization (MOMP), re-
sulting in release of mitochondrial factors such as cytochrome c,
AIF (apoptosis-inducing factor) and SMAC (second mitochondria-
derived activator of caspases) [13]. Whereas cytochrome c results
in activation of initiator caspase 9 [14], apoptosis by AIF was
reported as caspase-independent [15].
The initiator caspases -8, -9 and -10 activate downstream
effector caspases -3, -6 and -7, which cleave a large number of
death substrates to set apoptosis into work [16]. Effector caspases
and caspase-9 are critically inhibited by cIAPs (inhibitor of
apoptosis proteins), which thus can prevent extrinsic and intrinsic
pathways. Particularly, XIAP (chromosome x-linked IAP) has been
attributed a decisive role in apoptosis resistance of tumor cells [17].
IAPs themselves are negatively regulated by SMAC, which is
released from mitochondria upon apoptotic stimulation and binds
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[18].
Membrane ion channels serve fundamental cellular functions.
The group of Ca
2+-dependent potassium channels contributes to
cytoplasma membrane hyperpolarization thus facilitating Ca
2+
entry, a prerequisite for cell proliferation [19]. The family member
KCa3.1 (IK1) is inhibited by clotrimazole, commonly used in the
clinic as fungicide, as well as by the scorpion venom charybdo-
toxin. Systemic application of clotrimazole is however prevented
because of hepatotoxicity resulting from non-specific effects on
cytochrome P450. The alternative analogue TRAM-34 lacks
P450-inhibitory activity, thus avoiding these side effects [20].
Expression of IK1 was related to aberrant cell proliferation of
different types of tumor cells [19,21]. Induction of apoptosis was
not considered so far. Even decreased apoptosis has been reported
in thymocytes and erythrocytes upon IK1 inhibition [22,23]. The
particular new information of this manuscript is that the potassium
channel inhibitor TRAM-34 not only decreases melanoma cell
proliferation, but also efficiently enhances TRAIL-induced apop-
tosis via the mitochondrial pathway and is able to overcome
TRAIL resistance of melanoma cells.
Materials and Methods
Cell Culture
Human melanoma cell lines enclosed TRAIL-sensitive (A-375,
Mel-HO, SK-Mel-13, SK-Mel-28) and resistant cells (Mel-2a and
MeWo) [7]. Subclones with induced TRAIL resistance (SK-Mel-
13-TS, Mel-HO-TS, A-375-TS) derived from selection with
100 ng/ml TRAIL [8]. A-375 subclones stably transfected with
a pIRES-Bcl-2 plasmid (A375-Bcl-2) or pIRES (A375-Mock) had
been described previously [24]. Parental HCT-116 colon carci-
noma cells were from ATCC (Maryland, MD, USA), and
embryonic kidney cells (HEK-293) from DSMZ (Braunschweig,
Germany). The HCT-116 Bax knockout, Bak knockdown and
Bax/Bak double knockdown cells were kindly provided by B.
Vogelstein (John Hopkins Cancer Center, Baltimore, MD, USA)
[25]. Above cells were cultivated in DMEM (4.5 g/l glucose;
Gibco, Invitrogen, Karlsruhe, Germany) with 10% FCS and
antibiotics; HEK-293 furthermore received 1 mM pyruvate.
SW480 colon carcinoma and HeLa cervix carcinoma cells
(ATCC) were cultured in RPMI 1640 medium with L-glutamine
(Biochrom, Berlin, Germany). Culture conditions were 37uC, 5%
CO2. TRAIL-selected cells were continuously kept with 5 ng/ml
TRAIL until 24 h before treatment. Cells were plated in 6-, 24- or
96-well plates with 2610
5,5 610
4 and 5610
3 cells, respectively,
and treatment was started after 24 h.
For induction of apoptosis, the following agents were used:
TRAIL (Alexis, Gruenberg, Germany, ALX-201-073-C020,
20 ng/ml); the selective IK1 inhibitor TRAM-34 (20–80 mM,
kindly provided by H. Wulff, University of California, Davis, CA,
USA) [20]; the IK1 inhibitor charybdotoxin (Sigma-Aldrich,
Taufkirchen, Germany, 100–200 nM). For inhibition of apoptosis,
the following agents were used: selective DR4/DR5 antagonistic
antibodies (Alexis, ALX-804-297, ALX-804-298, 10 mg/ml; pre-
incubation for 1 h); the pancaspase inhibitor Q-VD-OPh (MP
Biomedicals, Ohio, USA; 10 mM, preincubation for 1 h).
Plasmid and siRNA Transfection
Transient cell transfection was performed in 6-well plates at
24 h after seeding (70% confluence); TRAM/TRAIL treatment
followed after another 24 h. An amount of 20 pmol siRNA and
4 ml TurboFect (Fermentas, St. Leon-Rot, Germany) per well were
used. The siRNAs for SMAC (sc-36505), Bid (sc-29800) and the
scrambled control (sc-37007) derived from Santa Cruz Biotech-
nology Inc. (Santa Cruz, CA, USA). For transient overexpression,
cells were transfected for 4 h at 37uC with 2.5 mg/ml plasmid
DNA and 0.1% DMRIE-C (Invitogen, Germany) in Opti-MEM
medium (Life Technologies, Carlsbad, CA, USA) [26]. A pCMV-
Sport6 plasmid with the full length sequence of human XIAP was
used (IRATp970H0655D; Source BioScience imaGenes, Berlin,
Germany). For IK1, a pcDNA plasmid with human IK1 [27] was
kindly supplied by A. Schwab (University of Mu ¨nster, Germany).
The plasmid pcDNA3.1 (Invitogen, Germany) served as mock
control.
Electrophysiological Recordings
Potassium currents were recorded at 25uC in a whole-cell patch-
clamp configuration [28], using an EPC10 amplifier and
appropriate software (HEKA Elektronik, Germany). Series resis-
tance errors were compensated in the range of 70–90%. Standard
bath solution [mM]: 5 KCl, 155 NaCl, 2 CaCl2, 10 HEPES,
pH 7.4. Internal pipette solution [in mM]: 130 KCl, 2 MgCl2,1 0
EGTA, 10 HEPES, 9.3 CaCl2, pH 7.4. Under these conditions,
intracellular Ca
2+ was at 1 mM. Currents were induced by 500 ms
voltage ramps, ranging from -100 to +50 mV. TRAM-34 (0.2 mM
in standard bath solution) was directly applied in the cell vicinity.
In time kinetics, mean currents were determined between –40 and
–25 mV.
Cell Proliferation, Apoptosis and Cytotoxicity
For proliferation analysis, cells were incubated for 4 h at 37uC
with 10% of WST-1 reagent (Roche diagnostics, Mannheim,
Germany), followed by determination of OD450 in an ELISA
reader. Non-treated controls were defined as 100%. For contin-
uously monitoring cell growth, the xCELLigence system (Roche
diagnostics; Penzberg, Germany) was applied.
For quantification of apoptosis, cell cycle analyses were
performed [29]. Cells harvested by trypsinisation were stained for
1 h with propidium iodide (Sigma-Aldrich, 200 mg/ml), and sub-
G1 fractions were quantified by flow cytometry in a FACS Calibur
(BD Bioscience, Bedford, USA). Cytotoxicity was determined in
parallel by measuring LDH activity in culture fluids applying a
cytotoxicity detection assay (Roche Diagnostics). Mitochondrial
membrane potential was measured with the fluorescent dye
TMRM
+ (Tetramethylrhodamine methyl ester perchlorate; Sig-
ma-Aldrich; 1 mM). Cells harvested by trypsinisation were stained
for 15 min at 37uC and were analyzed by flow cytometry.
Synergism Studies
For proving synergistic effects, melanoma cells were seeded in
24-well plates. Treatment started after 24 h with constant
concentrations ratios of TRAM-34 (20–80 mM) and TRAIL (10–
40 ng/ml). After 24 h of treatment, apoptosis was assessed by PI
staining, and monotreatments were compared to combinations.
Synergistic effects were proven by dose effect analyses resulting in
normalized isobologram images, as commonly described [30].
Combination effects were evaluated by the combination index
(CI), calculated according to the following equation: CI=D1/
Dx1+D2/Dx2. Here, Dx1 and Dx2 represent concentrations of
TRAIL and TRAM-34 needed to produce a certain apoptosis
effect when given alone, whereas D1 and D2 are the concentra-
tions needed for the apoptosis effect in the combination.
Synergistic effects are characterized by CI values of ,1, whereas
a CI of 1 indicates additive effects [30].
TRAM-34 Sensitizes for TRAIL-Induced Apoptosis
PLoS ONE | www.plosone.org 2 June 2012 | Volume 7 | Issue 6 | e39290Expression Analyses
For mRNA analysis, RNA was extracted with a NucleoSpin
RNA kit (Macherey-Nagel, Du ¨ren, Germany), and first strand
cDNA was produced with a kit of Fermentas (St. Leon-Roth,
Germany). Real-time PCR with 35 cycles (10 s at 95uC, 30 s at
60uC) in SYBR Green PCR master mix (Qiagen, Hilden,
Germany) was performed in a Masterplex thermocycler (Eppen-
dorf, Wesseling-Berzdorf, Germany). Primers for IK1 and b-actin
were from Qiagen (QuantiTect QT00003780 and QT00095431).
Relative IK1 expression was quantified according to the DCT
method using b-actin for normalization [31].
For analysis of receptor surface expression, cells harvested with
EDTA were stained with monoclonal antibodies against TRAIL
receptors (DR4, ALX-804-297; DR5, ALX-804-298, Alexis;
DcR1, sc-65308; DcR2, sc-65311, Santa Cruz; 1:100). Mouse
IgG1 (Ancell, # 278-010) served as control. After incubation with
a secondary antibody (Alexis, ALX 211-201, 1:100, 30 min),
surface expression was quantified by flow cytometry. SW480 and
HeLa cells served as positive controls for decoy receptors.
For Western blotting, total protein extracts were obtained by
cell lysis in 150 mM NaCl, 1 mM EDTA, 2 mM PMSF, 1 mM
leupeptin, 1 mM pepstatin, 0.5% SDS, 0.5% NP-40 and 10 mM
Tris-HCl (pH 7.5). Cytosolic and mitochondrial cell fractions were
obtained by a kit of PromoKine (Heidelberg Germany). Western
blotting on nitrocellulose membranes was described previously
[26].
Primary antibodies from Cell Signaling: cleaved caspase-3
(rabbit, 1:5000), caspase-3 (rabbit, 1:1000), caspase-8 (mouse,
1:1000), caspase-9 (rabbit, 1:1000), XIAP (rabbit, 1:1000), PARP
(rabbit, 1:1000). Primary antibodies from Santa Cruz: Mcl-1
(mouse, 1:200), Bcl-2 (mouse; 1:500; rabbit; 1:200), Bax (rabbit,
1:200), Bak (rabbit, 1:500), Bid (rabbit, 1:1000), cIAP2 (rabbit,
1:1000), survivin (mouse, 1:500), AIF (goat, 1:1000), SMAC
(mouse, 1:1000), IK1 (H-120, rabbit, 1:1000), GAPDH (mouse,
1:1000). Further antibodies: PUMA (Epitomics, rabbit, 1:1000),
Noxa (Pro Sci, rabbit, 1:500), DR4 (Abcam, rabbit, 1:500), DR5
(Abcam, rabbit, 1:500), cytochrome c (BD Biosciences, mouse,
1:1000), VDAC (Calbiochem; mouse; 1:5000), prohibitin (Thermo
Scientific, mouse, 1:1000). Secondary antibodies from Dako
(Hamburg, Germany; 1:5000): peroxidase-labeled goat anti-rabbit,
goat anti-mouse, rabbit anti-goat antibodies.
Statistical Analyses
Assays consisted of triplicates, and at least two independent
experiments were performed. Mean values and SDs were
calculated by enclosing all individual values of the independent
experiments (at least 6 values). Statistical significance was proven
by Student’s t-test (normal distribution) or Wilcoxon test (non-
normal distribution of data), and p-values of ,0.05 were
considered statistically significant.
Results
Antiproliferative Effects of TRAM-34
Significant expression of the potassium channel IK1 (46 kDa)
was observed in a panel of six melanoma cell lines by Western
blotting. HEK-293 cells were negative, and mock-transfected
cultures were used as negative controls. The specificity of the IK1
antibody was controlled by transient transfection with an IK1
plasmid, which restored expression of the 46/47 kDa protein band
in HEK-293 (Fig. 1A). Also expression of IK1 mRNA was proven
in melanoma cell lines by real-time PCR, whereas HEK-293
remained negative (Fig. 1B).
For demonstrating functional IK1 in melanoma cells, linear
potassium currents were recorded in response to a voltage ramp
protocol in A-375 under conditions of 1 mM intracellular Ca
2+.
Application of TRAM-34 reduced the current from 10 nA to
2 nA, suggesting IK1 as the dominant potassium channel in A-375
(Fig. 1C). Monitoring the time course of potassium currents at
voltage conditions between 240 mV and 225 mV revealed a
rapid and immediate decrease upon TRAM-34 treatment
(Fig. 1D).
Antiproliferative effects of TRAM-34 on melanoma cells were
determined by cell cycle analysis. Treatment with 40 mM
TRAM-34 for 24 h resulted in a partial G1 arrest and
diminished S-phase (Fig. 1E). Decreased dose-dependent cell
proliferation was seen for Mel-HO and A-375, as determined by
WST-1 assay (Fig. 1F; data not shown). Real-time cell analysis
revealed continuous antiproliferative effects by TRAM-34, which
started immediately after addition and resulted in a decrease of
2-3-fold at 72 h (Fig. 1G, 1H).
Sensitization of Melanoma Cells for TRAIL-induced
Apoptosis
For investigating strategies to overcome TRAIL resistance in
melanoma, a panel of TRAIL-sensitive and resistant melanoma
cell lines was studied. In addition, cell populations of A-375, SK-
Mel-13 and Mel-HO were used, which had been selected for
TRAIL resistance. Despite its antiproliferative activity (Fig. 1G),
TRAM-34 alone (20–80 mM) remained largely without effect on
apoptosis at 24, 48 and 72 h (Fig. 2A; data not shown). In
combination with TRAIL, however, TRAM-34 resulted in strong
enhancement of apoptosis in all sensitive and resistant cell
populations. Thus in TRAIL-sensitive A-375, Mel-HO, SK-Mel-
28 and SK-Mel-28 cells, apoptosis was induced by TRAM/
TRAIL in 18%–70% of cells corresponding to a factor of .4-fold,
as compared to TRAIL alone (Fig. 2A, 2B).
Also selected TRAIL-resistant cells (A-375-TS, Mel-HO-TS,
SK-Mel-13-TS) were highly responsive, resulting in apoptotic
rates between 13% and 60%, and even cell lines with pre-existing
TRAIL resistance (MeWo, Mel-2a) responded with 10% and 15%
apoptosis, respectively (Fig. 2A). Apoptosis appeared as the
dominant effect, as cytotoxicity remained rather unaffected at
24 h and at later times, as determined by LDH release (Fig. 2D;
data not shown). The proapoptotic effects of TRAM/TRAIL
resulted in strongly reduced cell proliferation, as determined by
WST-1 assay in A-375 and A-375-TS. Whereas TRAIL alone
decreased cell proliferation by 25% in A-375 and remained
without effect on A-375-TS, TRAM/TRAIL resulted in a
reduction of 95% and 75%, respectively (Fig. 2C).
For proving that enhanced apoptosis was mediated via IK1, the
alternative IK1 inhibitor charybdotoxin (CTX) was applied.
Comparable to TRAM-34, CTX (100–200 nM) only weakly
induced apoptosis in A-375 and A-375-TS but strongly enhanced
TRAIL sensitivity (Fig. 2E). As a final proof for the critical role of
IK1 in this setting, mock-transfected, IK1-negative HEK-293 cells
did not respond to TRAM/TRAIL, whereas strongly enhanced
apoptosis (27%) was obtained after transient transfection and
overexpression of IK1 (Fig. 2F).
Enhancement of TRAIL-induced apoptosis by TRAM-34
appeared as clearly synergistic, as proven by dose effect analyses
in A-375, A-375-TS, MeWo and Mel-HO. Thus keeping constant
concentration ratios, combinations of TRAIL (10–40 ng/ml) and
TRAM-34 (20–80 mM) were applied, and the effects of the
combination and single treatments were compared. In this way,
synergistic effects were proven for all three combinations in A-375
and A-375-TS (CI values ,0.4), for the two higher concentrations
TRAM-34 Sensitizes for TRAIL-Induced Apoptosis
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TRAIL/80 mM TRAM-34 in MeWo (CI=0.33; Fig. 3).
Upregulation of TRAIL Receptors
In agreement with the critical importance of TRAIL receptor
expression levels for melanoma cell sensitivity to TRAIL [7],
significant upregulation of DR4 and DR5 was seen in response to
TRAM-34. Thus DR5, which is expressed in all melanoma cell
lines, was generally upregulated at the levels of total cellular
protein and surface expression (Fig. 4A, 4B). Similarly, DR4 which
is expressed by A-375 and A-375-TS was upregulated in these cells
(Fig. 4C, Fig. 4D). No basal surface expression of TRAIL decoy
receptors DcR1 and DcR2 was found in A-375, SK-Mel-28, Mel-
HO and SK-Mel-13, as compared to the controls HeLa and
SW480. Only in MeWo, some expression of DcR2 was seen. The
treatment with TRAM-34, however, remained without effect on
decoy receptor expression in melanoma cells (Fig. 4E).
Figure 1. Antiproliferative effects by IK1 inhibition. (A) Protein expression of IK1 is shown in six melanoma cell lines. Negative control: mock-
transfected HEK-293; positive control: IK1-transfected HEK-293 cells. Equal protein loading (30 mg per lane) is proven by GAPDH. (B) Expression of IK1
mRNA in melanoma cell lines was determined by real-time PCR. The threshold of negative HEK-293 is indicated. Values were normalized to b-actin. (A,
B) Each two independent experiments revealed comparable results. (C) Voltage-dependent potassium currents were recorded in TRAM-34-treated A-
375, as compared to non-treated controls. The voltage range, used for subsequent time course, is indicated. (D) Time course of potassium currents in
A-375 after addition of TRAM-34 (t=0) is shown. Short arrowheads indicate the time interval for determination of the current/voltage dependency. (E)
Cell cycle analysis of TRAM-34-treated A-375 as compared to DMSO-treated controls. (F) Decreased proliferation in response to increasing
concentrations of TRAM-34 is shown for Mel-HO, as determined by WST-1 assay. Means and SDs are shown of three independent experiments, each
one consisting of triplicates. Statistical significance is indicated (*; p,0.005), when comparing TRAM-34-treated cells with DMSO-treated controls. (G,
H) Real-time growth curves of TRAM-34-treated A-375 and Mel-HO are compared to DMSO-treated controls. Cell indices were normalized at t=0.
doi:10.1371/journal.pone.0039290.g001
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TRAM/TRAIL-induced apoptosis, selective antagonistic antibod-
ies were applied. Clearly, apoptosis in DR4(+) A-375 was
preferentially blocked by the DR4 antagonist (70%), whereas
apoptosis in DR4(2) Mel-HO was largely blocked by the DR5
antagonist (70%) (Fig. 4F). These experiments proved that
TRAM-34 specifically enhanced TRAIL-induced apoptosis path-
ways via the TRAIL receptors.
Involvement of Caspases
In sensitive A-375, TRAIL alone already resulted in significant
activation of the caspase cascade, seen by cleavage products of
caspase-8 (18, 41, 43 kDa), caspase-9 (35, 37 kDa) and caspase-3
(15, 17, 20 kDa). Paradoxically, processing of caspase-8 and
caspase-3 was not further enhanced by the combination, whereas
some enhancement was seen for caspase-9 (Fig. 5A). Also in A-
375-TS, TRAIL alone resulted in processing of caspase-8 and of
caspase-3 to a 20 kDa premature product. Again, processing of
caspase-8 was not enhanced by the combination. Upon combined
treatment, however, caspase-9 processing and full processing of
caspase-3 to its mature cleavage products (15, 17 kDa) was seen.
Further proving enhanced caspase-3 activity, stronger cleavage of
the death substrate PARP (86 kDa) appeared in response to
combination treatment (Fig. 5A). Thus, mechanisms were
suggestive that enhanced activation of caspase-9 in both cell lines
and enabled full processing of caspase-3 in A-375-TS. The role of
caspases was also proven by the pancaspase inhibitor Q-VD-OPh,
which completely prevented TRAM/TRAIL-induced apoptosis
and restored cell viability (Fig. 5B; 5C).
Dependency on Mitochondria, Bax and Bcl-2
An involvement of mitochondrial apoptosis pathways was
evident in A-375 due to an enhanced decrease of the mitochon-
drial membrane potential Dym, as compared to TRAIL alone
(24 h: 22% R 56%; 48 h: 40% R 90%). TRAM-34 however did
not decrease Dym by itself, rather it resulted in a hyperpolariza-
Figure 2. Sensitization of melanoma cells for TRAIL-induced apoptosis. (A) Apoptosis (percentage of sub-G1 cells) was determined by cell
cycle analyses in nine melanoma cell lines treated with increasing concentrations of TRAM-34+/2 TRAIL. (B) Examples are shown of A-375 and A-375-
TS treated with the combination of 40 mM TRAM-34+ TRAIL (open graph) as compared to DMSO-treated controls (filled graph). (C, D) For A-375 and
A-375-TS, cell proliferation was determined by WST-1 (C) and cytotoxicity by LDH-release (D). (E) Apoptosis was monitored after treatment with two
concentrations of charybdotoxin (CTX) +/2 TRAIL. (F) Induction of apoptosis by TRAM-34+/2 TRAIL was determined in mock- and IK1-transfected
HEK-293 cells. Protein expression of IK1 at 24 h after transfection is shown in the inset, as determined by Western blotting. (A, C, D, E, F) Means and
SDs are shown of three independent experiments, each one consisting of triplicates. Statistical significance (*; p,0.005) is indicated, when comparing
TRAM/TRAIL-treated cells with TRAIL-treated cells.
doi:10.1371/journal.pone.0039290.g002
Figure 3. Synergism studies for TRAM-34 and TRAIL. (A) Induction of apoptosis (sub-G1 cells) is shown in four melanoma cell lines in response
to TRAM-34 (20–80 mM) and TRAIL (10–40 ng/ml), given alone or in combination. Calculated CI values are given in parenthesis above the bars of the
combinations. For dose effect analyses, relative concentrations of TRAM-34 were plotted against relative concentrations of TRAIL shown in
normalized isobolograms (insets). The hypotenuse indicates the line of additive effects, whereas values below are synergistic. Three independent
experiments revealed largely similar results.
doi:10.1371/journal.pone.0039290.g003
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data not shown). This suggested a direct effect of TRAM-34 on
mitochondria. In A-375-TS, there was no decrease of Dymb y
TRAIL indicating a block at the mitochondrial level. Under
combination treatment, however, the hyperpolarization of
TRAM-34 was shifted back at 24 h and even below the control
peak at 48 h (Fig. 6A).
The TRAM-34-mediated increase of Dym was clearly depen-
dent on IK1, as seen in mock-transfected and IK1-transfected
HEK-293. Whereas there was no increase of Dym in mock-
transfected cells in response to TRAM-34, the effect was restored
by IK1 transfection. Again, the hyperpolarization was shifted back
by the combination with TRAIL (Fig. 6B).
The effects on mitochondria were not related to any changes at
the expression level of Bcl-2 proteins, as proven for a panel of pro-
and anti-apoptotic factors (Fig. 6C). TRAM/TRAIL-mediated
apoptosis was however clearly dependent on Bax, and it was
abrogated by Bcl-2 overexpression. Thus, in Bax
+/Bak
+ HCT-116
colon carcinoma cells, TRAIL-induced apoptosis was similarly
enhanced by TRAM-34 (14% R 50%). Apoptosis was almost
completely abrogated in Bax knockout and in Bax/Bak double
knockdown cells, whereas Bak knockdown had only little effect
(Fig. 6D). Similarly, stable overexpression of Bcl-2 (A375-Bcl-2)
completely protected against the proapoptotic effects of TRAM/
TRAIL (Fig. 6E). Both, loss of Dym by combination treatment
and membrane hyperpolarization by TRAM-34, were completely
blocked by Bcl-2 overexpression (Fig. 6F). The experiments proved
the critical role of mitochondria for TRAM-34 proapoptotic
effects.
Release of Mitochondrial Factors
Direct effects of TRAM-34 on mitochondria could be explained
by the presence of IK1 in mitochondrial membranes. Indeed,
significant IK1 expression was seen in mitochondrial extracts,
which remained unchanged upon treatment (Fig. 7A). In
agreement with its Bax dependency (Fig. 6D), mitochondrial
translocation of Bax was seen in A-375 and A-375-TS in response
to TRAM-34 alone or combination treatment. This happened at
4 h, thus before any apoptosis was induced, indicative for an initial
step (Fig. 7B).
Of particular note was the strong release of mitochondrial
factors as cytochrome c, AIF and SMAC already at 4 h of
combination treatment (Fig. 7C). The same response was seen in
A-375, in A-375-TS and A-375-Mock at 24 h of treatment,
whereas the release of mitochondrial factors was prevented by Bcl-
2 overexpression in A375-Bcl-2 (data not shown).
Figure 4. Death receptor expression in response to TRAM-34. (A, B) Expression of DR5 is shown in five melanoma cell lines in response to
TRAM-34 (40 mM, +), and (C, D) expression of DR4 is shown in A-375 and A-375-TS, as compared to DMSO-treated controls (2). Total protein
expression was determined by Western blotting, and surface expression was determined by flow cytometry. (E) Expression of DcR1 and DcR2 is
shown by flow cytometry in five melanoma cell lines in response to TRAM-34. HeLa and SW480 cells served as positive controls for DcR1 and DcR2,
respectively. IgG1-stained cells served as negative controls. Three (A, C) or two (E) independent experiments, with each time triplicates revealed
highly similar results. (F) Apoptosis in response to TRAM/TRAIL was monitored in A-375 and Mel-HO after blocking DR4 and/or DR5 by selective
antagonistic antibodies (mean values and SDs of two independent experiments, each one with triplicates). Statistical significance is indicated (*;
p,0.005), when comparing combined treatment with TRAIL alone.
doi:10.1371/journal.pone.0039290.g004
Figure 5. Caspase activation in response to TRAM and TRAIL. (A) Processing of caspase-8, -9 and -3 in A-375 and A-375-TS in response to
TRAM-34 (40 mM) and TRAIL is shown by Western blotting. Two independent experiments revealed comparable results. (B) Apoptosis (% of sub-G1
cells) in A-375 and A-375-TS is shown in response to TRAIL, TRAM-34 and the pancaspase inhibitor Q-VD-OPh (10 mM, 1 h pretreatment). (C) Cell
proliferation was determined by WST-1. (B, C) Mean values and SDs are shown of two independent experiments, each one with triplicates. Statistical
significance of abrogated apoptosis and recovered cell proliferation by Q-VD-OPh is indicated (*; p,0.005).
doi:10.1371/journal.pone.0039290.g005
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PLoS ONE | www.plosone.org 8 June 2012 | Volume 7 | Issue 6 | e39290Figure 6. Dependency on Bax and Bcl-2. (A, B, F) Mitochondrial membrane potential (Dym) was measured in A-375, A-375-TS, mock and IK1-
transfected HEK-293, A375-Mock and A375-Bcl-2 at 24 h and 48 h of treatment with TRAM-34 (40 mM) +/2 TRAIL. Treated cells (open graphs) were
compared with DMSO-treated controls (grey). Each three independent experiments showed comparable results. (C) Expression of Bcl-2 proteins was
determined by Western blotting in A-375 and A-375-TS in response to TRAM-34 (40 mM) +/2 TRAIL. Two independent experiments showed
comparable results. (D, E) Apoptosis induced by TRAM/TRAIL was investigated in (D) HCT-116 parental cells (Bax
+, Bak
+) and in subclones with
knockdown for Bax and/or Bak, as well as in (E) A-375 cells stably transfected with Bcl-2 (A375-Bcl-2) and mock transfected controls. Expression of Bcl-
2 proteins was controlled by Western blotting (insets). Statistical significance is indicated (*; p,0.005) for comparison of parental cells and mock
controls.
doi:10.1371/journal.pone.0039290.g006
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interconnected through the proapoptotic Bcl-2 protein Bid, which
is activated by caspase-8. We investigated its role in TRAM/
TRAIL-induced apoptosis, by applying anti-Bid siRNA in A-375
and A-375-TS. Bid knockdown strongly diminished apoptosis by
two to threefold (Fig. 8A), thus proving the dependency on the
mitochondrial amplification loop and again underlining, that
specific TRAIL pathways were enhanced (Fig. 8A).
The Decisive Role of the SMAC-cIAP Rheostat
According to caspase analysis (Fig. 5A), inhibited caspase-3
appeared as limiting TRAIL-induced apoptosis. This was an
indication for the antiapoptotic function of cIAPs. Melanoma cell
lines revealed significant expression of cIAPs as survivin, cIAP-2
and XIAP as well as of the cIAP antagonist SMAC (Fig. 8B). For
investigating the role of XIAP, it was overexpressed by plasmid
Figure 7. Mitochondrial release of proapoptotic factors. (A)
Mitochondrial extracts of A-375, treated as indicated with TRAM-34 and
TRAIL for 24 h, were analyzed for IK1 by Western blotting. Comparable
amounts of mitochondrial extracts were loaded as proven by
incubation with prohibitin antibody. A cytosolic extract (Cyto) as well
as total protein extracts of mock or IK1-transfected HEK-293 served as
controls. (B, C) Mitochondrial (Mito) and cytosolic extracts (Cyto) of A-
375 and A-375-TS treated for 4 h with TRAM-34 (40 mM) +/2TRAIL were
investigated by Western blotting. Equal loading was proven by the
mitochondrial protein VDAC and cytosolic protein GAPDH, respectively.
VDAC applied to cytosolic extracts ruled out contaminations with
mitochondria.
doi:10.1371/journal.pone.0039290.g007
Figure 8. Dependency on XIAP, Bid and SMAC. (A, C, D) The
sensitivity of A-375 and A-375-TS cells for TRAM/TRAIL-induced
apoptosis is shown (A) after siRNA-mediated Bid knockdown, (C)
plasmid-mediated XIAP overexpression and (D) siRNA-mediated SMAC
knockdown. The respective mock controls are shown for comparison.
Apoptosis (% of sub-G1 cells) and cytotoxicity (LDH release) is shown at
24 h of treatment. Mean values and SDs of three (XIAP, SMAC) or two
independent experiments (Bid) are shown; each experiment consisted
of triplicates. Statistical significance is indicated (*; p,0.005), when
comparing to the respective mock controls. Overexpression or
downregulation is shown in insets. (B) Expression of cIAPs (survivin,
XIAP and cIAP-2) as well as of SMAC was analyzed by Western blotting
in total protein extracts of melanoma cell lines.
doi:10.1371/journal.pone.0039290.g008
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XIAP as a major inhibitor of TRAIL-induced apoptosis in
melanoma cells, its overexpression strongly diminished TRAM/
TRAIL-induced apoptosis by 60–70%, as compared to mock-
transfected cells (Fig. 8D).
In light of the strong release of mitochondrial AIF, cytochrome
c and SMAC (Fig. 7C), the question was which of these factors
could provide enhanced TRAM/TRAIL-induced apoptosis.
Clearly supporting the decisive role of SMAC for overcoming
inducible TRAIL resistance, its siRNA-mediated downregulation
completely protected A-375-TS against the proapoptotic effects of
TRAM/TRAIL (Fig. 8D). Also in parental A-375, SMAC
knockdown strongly limited apoptosis to the level induced by
TRAIL itself (Fig. 8C, 8D). Cytotoxicity was largely unaffected by
these treatments at 24 h (Fig. 8A, 8C, 8D). Thus, the enhancement
of TRAIL-induced apoptosis by TRAM-34 was essentially based
on the release of SMAC. The rheostat of released SMAC and
antiapoptotic cIAPs appeared as a critical level regulating TRAIL
sensitivity in melanoma cells.
Discussion
The death ligand TRAIL appears as a promising antitumor
strategy, due to apoptosis induction in cancer cells, while normal
cells were largely spared [32,33]. However, clinical trials with
TRAIL or TRAIL receptor agonists have shown only limited
response so far in solid tumors [34,35]. Insufficient efficacy may be
attributed to inducible resistance, as has been seen in different
tumor models, also in melanoma cells [8,36]. Sensitization thus
appears as an important step for establishing TRAIL-based
therapies, and multiple strategies have been applied to enhance
melanoma cell sensitivity to TRAIL [37–40].
A completely new strategy is presented here that is based on
selective inhibition of the calcium-dependent potassium channel
IK1, which has been reported as upregulated in several types of
human cancers [21,41,42]. Also in melanoma cells, we have
previously demonstrated IK1-dependent transmembrane potassi-
um currents [28]. Here we prove IK1 mRNA and protein
expression in a series of melanoma cell lines, thus suggesting IK1
expression as a characteristic feature of melanoma.
Inhibitors of IK1 are represented by clotrimazole and the
scorpion venom charybdotoxin. The clotrimazole analogue
TRAM-34 lacks non-specific inhibition of cytochrome P450,
which is a clotrimazole side effect and associated with liver toxicity
[20]. The specificity of TRAM-34-mediated effects via IK1 was
proven here in IK1-negative HEK-293 cells, which did not
respond, whereas IK1-transfected cells recovered responsiveness.
IK1 has been related to aberrant tumor cell proliferation and
migration [19,43,44], and antiproliferative effects upon IK1
inhibition were reported in different tumor cells [41]. In
agreement, we show significant growth inhibition by TRAM-34
in melanoma cells.
Induction of apoptosis has so far not been related to IK1
inhibition. Rather, calcimycin-induced apoptosis was suppressed
in lymphocytes by charybdotoxin and clotrimazole [22], and
TRAM-34 suppressed the proapoptotic effects of cisplatin in
epidermoid cancer cells [42]. However, combinations with death
ligands had not been considered so far. In agreement with
previous reports, TRAM-34 itself did not trigger apoptosis in
melanoma cells. However, the combination with TRAIL syner-
gistically enhanced apoptosis, and both pre-existing and inducible
TRAIL resistance were overcome. Of particular note, all of nine
melanoma cell lines were responsive, indicating a general
mechanism that was targeted by TRAM-34. Thus, the relation
of potassium channels to apoptosis regulation appears in a new
light.
As concerning the mechanisms how TRAM-34 may enhance
TRAIL-induced apoptosis, an upregulation of both agonistic
TRAIL receptors was seen. This appears of particular interest, as
downregulation of TRAIL receptors played an important role in
inducible TRAIL resistance of melanoma cells [8], which is thus
crossed by TRAM-34. Upregulation of TRAIL receptors has also
been seen with resveratrol and indirubin [37,40]. In contrast,
TRAIL decoy receptors DcR1 and DcR2 appeared of no role in
TRAM-34/TRAIL-induced apoptosis.
Remarkably however, processing of initiator caspase-8 was not
significantly enhanced by combined TRAM/TRAIL treatment
as compared to TRAIL alone, indicating the critical role of
downstream regulation steps. Indeed, significant activation of
mitochondrial apoptosis pathways was seen, as decreased
mitochondrial membrane potential and release of proapoptotic
mitochondrial factors (cytochrome c, AIF and SMAC). This
mitochondrial activation appeared as essential for TRAM/
TRAIL-induced apoptosis. Firstly, it preceded apoptosis induc-
tion, and secondly, apoptosis was strongly dependent on Bcl-2
proteins. Thus Bax knockout or Bcl-2 overexpression or siRNA-
mediated knockdown of Bid strongly diminished TRAM/
TRAIL-induced apoptosis. The critical role of mitochondrial
pathways for TRAIL sensitization of melanoma cells has also
been seen for indirubin and UVB [39,40], thus underlining their
importance for apoptosis induction in melanoma.
The question was how TRAM-34 could activate mitochondrial
pathways. Potassium channels have mainly been considered as
located in the cytoplasma membrane and controlling the
membrane potential [19]. However, potassium conductance has
also been identified across the mitochondrial membrane, which
was mediated in lymphocytes by the voltage-gated potassium
channel Kv1.3 [45]. Similarly, IK1 activity has recently been
identified by patch clamp analysis in mitochondria of colon
carcinoma cells [46]. Clearly supporting these findings, we show
here significant IK1 expression in mitochondrial fractions of
melanoma cells.
The mitochondrial activity of IK1 was clearly visible by
hyperpolarization of Dym in response to TRAM-34. This effect
was clearly proven as dependent on IK1, as IK1-negative cells did
not respond, but hyperpolarization was re-established after IK1
transfection. A similar effect on Dym hyperpolarization was
observed upon Kv1.3 inhibition preceding apoptosis [47],
suggesting this step as characteristic for apoptosis mediated via
potassium channels. This hyperpolarization effect may result from
the role of the mitochondrial potassium influx in antagonizing
increased Dym by proton export [48].
Strongly relating potassium channels with the regulation of
apoptosis, an physical interaction between Bax and Kv1.3 was
reported in lymphocytes, which appeared as necessary for Bax-
induced apoptosis [47]. Supporting the critical role of Bax, we see
here a clear dependency of TRAM/TRAIL-induced apoptosis on
Bax as well as mitochondrial translocation of Bax in response to
TRAM-34, as an early effect. Thus the repertoire of IK1 activities
has to be extended by the induction of mitochondrial apoptosis
pathways.
Coming back to the roles of mitochondrial factors released in
course of TRAM/TRAIL-induced apoptosis, caspase-indepen-
dent AIF [15] may play a less important role, as apoptosis was
abrogated by caspase inhibitors. Cytochrome c, which activates
caspase-9 [49], may contribute to the sensitization of A-375-TS
and A-375. Most suitable for explaining enhanced apoptosis by
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released SMAC.
Proteins of the IAP family are frequently overexpressed in
cancer cells and have been implicated in tumor growth,
pathogenesis and chemoresistance [50].
To prevent cell death, XIAP directly binds to processed caspase-
9 and caspase-3 [51]. Also melanoma cells revealed significant
expression of cIAPs, suggesting that this was the brake, which
prevented full caspase-3 activation in response to TRAIL. The
hypothesis was that SMAC release induced by TRAM/TRAIL
resulted in XIAP neutralization and release of caspase-3 activity.
The hypothesis was proven by SMAC knockdown, which
completely abrogated TRAM/TRAIL-induced apoptosis in
TRAIL-resistant A-375-TS. Some remaining apoptosis in parental
A-375 may depend on a residual direct caspase cascade in these
cells.
The important role of the SMAC/XIAP rheostat has also been
addressed in other studies leading to the development of small
molecule XIAP inhibitors to enhance TRAIL sensitivity [51,52].
Its decisive role for TRAM/TRAIL-induced apoptosis in mela-
noma cells was further supported by XIAP overexpression, which
diminished apoptosis by 50%. The particular function of TRAM-
34 in this setting was the opening of the mitochondrial pathway
through Bax activation. The finding that XIAP overexpression did
not completely prevent TRAM/TRAIL-induced apoptosis fur-
thermore indicated the presence of a master regulator, which was
able to undermine XIAP activity.
In view of development of effective therapies for melanoma,
TRAM-34 and TRAIL may be considered. Both TRAIL and
clotrimazole analogues have been seen in clinical trials with only
minor side effects reported [34,53]. Due to the data in this
manuscript, their combination appears as suggestive for efficient
induction of apoptosis in melanoma.
Acknowledgments
TRAM-34 was kindly supplied by Dr. Heike Wulff, Department of
Pharmacology, University of California, Davis, CA, USA, and the IK1
plasmid was kindly provided by Prof. Albrecht Schwab, University of
Mu ¨nster, Germany. The HCT-116 Bax knockout, Bak knockdown and
Bax/Bak double knockdown cells were kindly provided by B. Vogelstein
(John Hopkins Cancer Center, Baltimore, MD, USA).
Author Contributions
Conceived and designed the experiments: SAQ RS JE. Performed the
experiments: SAQ AB NB KF. Analyzed the data: SAQ JE NB KF RS.
Contributed reagents/materials/analysis tools: JE RS. Wrote the paper: JE
SAQ.
References
1. Garbe C and Leiter U (2009) Melanoma epidemiology and trends. Clin.-
Dermatol. 27: 3–9.
2. Eberle J, Kurbanov B M, Hossini A M, Trefzer U, Fecker L F (2007)
Overcoming apoptosis deficiency of melanoma-hope for new therapeutic
approaches. Drug Resist.Updat. 10: 218–234.
3. Lemke J, Noack A, Adam D, Tchikov V, Bertsch U, et al. (2010) TRAIL
signaling is mediated by DR4 in pancreatic tumor cells despite the expression of
functional DR5. Journal of Molecular Medicine-Jmm 88: 729–740.
4. Degli-Esposti MA SPWHWJHCDRGRSC (1997) Cloning and characterization
of TRAIL-R3, a novel member of the emerging TRAIL receptor family.
J.Exp.Med 186: 1165–1170.
5. Degli-Esposti MA, Dougall W C, Smolak P J, Waugh J Y, Smith C A, et al.
(1997) The novel receptor TRAIL-R4 induces NF-kappa B and protects against
TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity
7: 813–820.
6. Koschny R, Walczak H, and Ganten T M (2007) The promise of TRAIL -
potential and risks of a novel anticancer therapy. Journal of Molecular Medicine-
Jmm 85: 923–935.
7. Kurbanov BM, Geilen C C, Fecker L F, Orfanos C E, Eberle J (2005) Efficient
TRAIL-R1/DR4-mediated apoptosis in melanoma cells by tumor necrosis
factor-related apoptosis-inducing ligand (TRAIL). J.Invest Dermatol. 125: 1010–
1019.
8. Kurbanov BM, Fecker L F, Geilen C C, Sterry W, Eberle J (2007) Resistance of
melanoma cells to TRAIL does not result from upregulation of antiapoptotic
proteins by NF-kappaB but is related to downregulation of initiator caspases and
DR4. Oncogene 26: 3364–3377.
9. Zhang XD, Wu JJ, Gillespie S, Borrow J, and Hersey P (2006) Human
melanoma cells selected for resistance to apoptosis by prolonged exposure to
tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to
necrotic cell death induced by cisplatin. Clinical Cancer Research 12: 1355–
1364.
10. Tait SWG and Green D R (2010) Mitochondria and cell death: outer membrane
permeabilization and beyond. Nature Reviews Molecular Cell Biology 11: 621–
632.
11. Mellier G, Huang S, Shenoy K, and Pervaiz S (2010) TRAILing death in
cancer. Mol.Aspects Med. 31: 93–112.
12. Chipuk JE, Moldoveanu T, Llambi F, Parsons M J, Green D R (2010) The
BCL-2 Family Reunion. Molecular Cell 37: 299–310.
13. Du CY, Fang M, Li Y C, Li L, Wang X D (2000) Smac, a mitochondrial protein
that promotes cytochrome c-dependent caspase activation by eliminating IAP
inhibition. Cell 102: 33–42.
14. Fischer U, Janicke R U, Schulze-Osthoff K (2003) Many cuts to ruin: a
comprehensive update of caspase substrates. Cell Death and Differentiation 10:
76–100.
15. Norberg E, Orrenius S, Zhivotovsky B (2010) Mitochondrial regulation of cell
death: Processing of apoptosis-inducing factor (AIF). Biochemical and Biophys-
ical Research Communications 396: 95–100.
16. Riedl SJ, Shi Y (2004) Molecular mechanisms of caspase regulation during
apoptosis. Nat.Rev.Mol.Cell Biol. 5: 897–907.
17. Deveraux QL, Reed T C (1999) IAP family proteins - suppressors of apoptosis.
Genes & Development 13: 239–252.
18. Chai JJ, Du C Y, Wu J W, Kyin S, Wang X D, et al. (2000) Structural and
biochemical basis of apoptotic activation by Smac/DIABLO. Nature 406: 855–
862.
19. Wickenden A (2002) K(+) channels as therapeutic drug targets. Pharmacol.Ther.
94: 157–182.
20. Wulff H, Miller M J, Hansel W, Grissmer S, Cahalan M D, et al. (2000) Design
of a potent and selective inhibitor of the intermediate-conductance Ca
2+-
activated K+ channel, IKCa1: a potential immunosuppressant. Proc.Natl.A-
cad.Sci.U.S.A 97: 8151–8156.
21. Schonherr R (2005) Clinical relevance of ion channels for diagnosis and therapy
of cancer. Journal of Membrane Biology 205: 175–184.
22. Elliott JI and Higgins C F (2003) IKCa1 activity is required for cell shrinkage,
phosphatidylserine translocation and death in T lymphocyte apoptosis. EMBO
Rep. 4: 189–194.
23. Lang PA, Kaiser S, Myssina S, Wieder T, Lang F, et al. (2003) Role of Ca
2+-
activated K+ channels in human erythrocyte apoptosis. Am.J.Physiol Cell
Physiol 285: C1553–C1560.
24. Raisova M, Hossini A, Riebeling C, Wieder T, Daniel P, et al. (2001) Apoptosis
resistance in human melanoma cells. Journal of Investigative Dermatology 117:
168.
25. Gillissen B, Wendt J, Richter A, Richter A, Muer A, et al. (2010) Endogenous
Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in
Bax-deficient carcinoma. J.Cell Biol. 188: 851–862.
26. Eberle J, Fecker L F, Hossini A M, Wieder T, Daniel P T, et al. (2003) CD95/
Fas signaling in human melanoma cells: conditional expression of CD95L/FasL
overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits
growth and progression of human melanoma xenotransplants. Oncogene 22:
9131–9141.
27. Schwab A, Nechyporuk-Zloy V, Gassner B, Schulz C, Kessler W, et al. (2012)
Dynamic redistribution of calcium sensitive potassium channels (hKCa3.1) in
migrating cells. Journal of Cellular Physiology 227: 686–696.
28. Gavrilova-Ruch O, Schonherr K, Gessner G, Schonherr R, Klapperstuck T, et
al. (2002) Effects of imipramine on ion channels and proliferation of IGR1
melanoma cells. J.Membr.Biol. 188: 137–149.
29. Riccardi C, Nicoletti I (2006) Analysis of apoptosis by propidium iodide staining
and flow cytometry. Nat.Protoc. 1: 1458–1461.
30. Chou TC (2006) Theoretical basis, experimental design, and computerized
simulation of synergism and antagonism in drug combination studies.
Pharmacological Reviews 58: 621–681.
31. Silver N, Best S, Jiang J, Thein S L (2006) Selection of housekeeping genes for
gene expression studies in human reticulocytes using real-time PCR. Bmc
Molecular Biology 7.
32. Walczak H, Miller R E, Ariail K, Gliniak B, Griffith T S, et al. (1999)
Tumoricidal activity of tumor necrosis factor related apoptosis-inducing ligand
in vivo. Nature Medicine 5: 157–163.
33. Ashkenazi A (2002) Targeting death and decoy receptors of the tumour-necrosis
factor superfamily. Nature Reviews Cancer 2: 420–430.
TRAM-34 Sensitizes for TRAIL-Induced Apoptosis
PLoS ONE | www.plosone.org 12 June 2012 | Volume 7 | Issue 6 | e3929034. Herbst RS, Eckhardt S G, Kurzrock R, Ebbinghaus S, O’Dwyer P J, et al.
(2010) Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a
dual proapoptotic receptor agonist, in patients with advanced cancer.
J.Clin.Oncol. 28: 2839–2846.
35. Soria JC, Mark Z, Zatloukal P, Szima B, Albert I, et al. (2011) Randomized
Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin,
and Bevacizumab in Advanced Non-Small-Cell Lung Cancer. Journal of
Clinical Oncology 29: 4442–4451.
36. Li Y, Wang H, Wang Z, Makhija S, Buchsbaum D, et al. (2006) Inducible
resistance of tumor cells to tumor necrosis factor-related apoptosis-inducing
ligand receptor 2-mediated apoptosis by generation of a blockade at the death
domain function. Cancer Research 66: 8520–8528.
37. Ivanov VN, Partridge M A, Johnson G E, Huang S X, Zhou H, et al. (2008)
Resveratrol sensitizes melanomas to TRAIL through modulation of antiapopto-
tic gene expression. Exp.Cell Res. 314: 1163–1176.
38. Jiang CC, Chen L H, Gillespie S, Kiejda K A, Mhaidat N, et al. (2007)
Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related
apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via
the unfolded protein response. Cancer Res. 67: 5880–5888.
39. Hornle M, Peters N, Thayaparasingham B, Vorsmann H, Kashkar H, et al.
(2010) Caspase-3 cleaves XIAP in a positive feedback loop to sensitize melanoma
cells to TRAIL-induced apoptosis. Oncogene.
40. Berger A, Quast S A, Plotz M, Hein M, Kunz M, et al. (2010) Sensitization of
melanoma cells for death ligand-induced apoptosis by an indirubin derivative-
Enhancement of both extrinsic and intrinsic apoptosis pathways. Biochem.-
Pharmacol.
41. Chou CC, Lunn C A, and Murgolo N J (2008) KCa3.1: target and marker for
cancer, autoimmune disorder and vascular inflammation? Expert.Rev.Mol.-
Diagn. 8: 179–187.
42. Lee EL, Hasegawa Y, Shimizu T, Okada Y (2008) IK1 channel activity
contributes to cisplatin sensitivity of human epidermoid cancer cells. Am.J.Phy-
siol Cell Physiol 294: C1398–C1406.
43. Schwab A, Reinhardt J, Schneider S W, Gassner B, Schuricht B (1999) K+
channel-dependent migration of Fibroblasts and human melanoma cells.
Cellular Physiology and Biochemistry 9: 126–132.
44. Schmidt J, Friebel K, Schonherr R, Coppolino M G, Bosserhoff A K (2010)
Migration-associated secretion of melanoma inhibitory activity at the cell rear is
supported by KCa3.1 potassium channels. Cell Res. 20: 1224–1238.
45. Szabo I, Bock J, Jekle A, Soddemann M, Adams C, et al. (2005) A novel
potassium channel in lymphocyte mitochondria. Journal of Biological Chemistry
280: 12790–12798.
46. Sassi N, De Marchi U, Fioretti B, Biasutto L, Gulbins E, et al. (2010) An
investigation of the occurrence and properties of the mitochondrial intermedi-
ate-conductance Ca(2+)-activated K(+) channel mtK(Ca)3.1. Biochim.Biophy-
s.Acta 1797: 1260–1267.
47. Szabo I, Bock J, Grassme H, Soddemann M, Wilker B, et al. (2008)
Mitochondrial potassium channel Kv1.3 mediates Bax-induced apoptosis in
lymphocytes. Proceedings of the National Academy of Sciences of the United
States of America 105: 14861–14866.
48. Garlid KD, Paucek P (2003) Mitochondrial potassium transport: the K+ cycle.
Biochimica et Biophysica Acta-Bioenergetics 1606: 23–41.
49. Huttemann M, Pecina P, Rainbolt M, Sanderson T H, Kagan V E, et al. (2011)
The multiple functions of cytochrome c and their regulation in life and death
decisions of the mammalian cell: From respiration to apoptosis. Mitochondrion
11: 369–381.
50. Fulda S, Vucic D (2012) Targeting IAP proteins for therapeutic intervention in
cancer. Nat.Rev.Drug Discov. 11: 109–124.
51. Vogler M, Walczak H, Stadel D, Haas T L, Genze F, et al. (2009) Small
Molecule XIAP Inhibitors Enhance TRAIL-Induced Apoptosis and Antitumor
Activity in Preclinical Models of Pancreatic Carcinoma. Cancer Research 69:
2425–2434.
52. Zhang XD, Zhang X Y, Gray C P, Nguyen T, Hersey P (2001) Tumor necrosis
factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma
is regulated by smac/DIABLO release from mitochondria. Cancer Res. 61:
7339–7348.
53. Ataga KI, Stocker J (2009) Senicapoc (ICA-17043): a potential therapy for the
prevention and treatment of hemolysis-associated complications in sickle cell
anemia. Expert Opinion on Investigational Drugs 18: 231–239.
TRAM-34 Sensitizes for TRAIL-Induced Apoptosis
PLoS ONE | www.plosone.org 13 June 2012 | Volume 7 | Issue 6 | e39290